Shots:
- The MHLW has approved Incyte’s Minjuvi + rituximab & lenalidomide for the treatment of adults with r/r FL (Grade 1-3a) who received ≥1L of systemic therapy
- Approval was based on the P-III (inMIND) trial (N=654) assessing Minjuvi combination vs PBO + rituximab & lenalidomide in r/r FL or r/r nodal, splenic or extranodal MZL pts (≥18yrs.), incl. those of Japan
- Trial met its 1EP of improved PFS (mPFS: 22.4 vs 13.9mos.), while IRC-assessed PFS was consistent with results (mPFS was not reached vs 16mos.)
Ref: Incyte | Image: Incyte | Press Release
Related News: Incyte Reports Positive P-I Data of INCA033989 in Essential Thrombocythemia (ET) at ASH 2025
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
